Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia

Blood

Volumn 89, Issue 1, 1997, Pages 243-255

  Banker, Deborah E ^a   Groudine, Mark ^b   Norwood, Tom ^b   Appelbaum, Frederick R ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CHROMOSOME TRANSLOCATION 15; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; GAMMA IRRADIATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KARYOTYPE; PRIORITY JOURNAL;

EID: 0031030034     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.1.243     Document Type: Article

References (29)

1. Li X, Gong J, Feldman E, Seiter K, Traganos F, Darzynkiewicz Z: Apoptotic cell death during treatment of leukemias. Leuk Lymphoma 13:65-70, 1994
2. Tosi P, Visani G, Ottaviani E, Manfroi S, Zinzani PL, Tura S: Fludarabine + ARA-C + G-CSF: Cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 8:2076-2082, 1994
3. Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, Deisseroth AB: PML/RARa, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Clin Cancer Res 1:583-590, 1995
4. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 86:1148, 1995
5. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
6. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148, 1994
7. Zhang W, Hu G, Estey E, Hester J, Deisseroth A: Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 7:1645, 1992
8. Guillouf C, Graña X, Selvakumaran M, De Luca A, Giordano A, Hoffman B, Liebermann DA: Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: Blocking p53-induced apoptosis unmasks GI arrest. Blood 85:2691, 1995
9. Campos L, Rouault J-P, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Maguad J-P, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1993
10. Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ, Hall AG: The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol 88:105, 1994
11. Huang P, Robertson LE, Wright S, Plunkett W: High molecular weight DNA fragmentation: A critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res 1:1005, 1995
12. Ohta H, Sweeney EA, Masamune A, Yatomi Y, Hakomori S, Igarashi Y: Induction of apoptosis by sphingosine in human leukemic HL-60 cells: A possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation. Cancer Res 55:691, 1995
13. Koopman G, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, van Oers MHJ: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415, 1994
14. Endresen PC, Prytz PS, Aarbakke J: A new flow cytometric method for discrimination of apoptotic cells and detection of their cell cycle specificity through staining of F-actin and DNA. Cytometry 20:162, 1995
15. Wu S-Q, Voelkerding KV, Sabatini L, Chen X-R, Huang J, Meisner LF: Extensive amplication of bcr/abl fusion genes clustered on three marker chromosomes in human leukemic cell line K-562. Leukemia 9:858, 1995
16. Terstappen LWMM, Johnson D, Mickaels RA, Chen J, Olds G, Hawkins, JT, Loken MR, Lebin J: Multidimensional flow cytometric blood cell differentiation without erythrocyte lysis. Blood Cells 17:585, 1991
17. Rabinovitch PS, Torres RM, Engel D: Simultaneous cell cycle analysis and two-color surface immunofluorescence using 7-aminoactinomycin D and single laser excitation: Applications to study of cell activation and the cell cycle of murine Ly-1 B cells. J Immunol 136:2769, 1986
18. Darzynkiewicz Z, Traganos F, Kapuscinski J, Staiano-Coico L, Melamed MR: Accessibility of DNA in situ to various fluorochromes: Relationship to chromatin changes during erythroid differentiation of Friend leukemia cells. Cytometry 5:355, 1984
19. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ: Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogentic group. Blood 84:111a, 1994 (abstr, suppl 1)
20. Head D, Kopecky KJ, Weick J, Flies JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams W, Hewlett J, Wilman C, Appelbaum FR: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717, 1995
21. Campos L, Sabido O, Rouault J-P, Guyotat D: Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84:595, 1994
22. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA, Della Porta G: Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79:1291, 1992
23. Shinohara S, Sawad T, Nishioka Y, Tohma S, Kisaki T, Inoue T, Ando K, Ikeda M, Fujii H, Ito K: Differential expression of Fas antigen and BCL-2 protein on CD4+ T cells, CD8+ T cells, and monocytes. Cell Immunol 163:303, 1995
24. Lowenberg B, van Putten WL, Touw IP, Delwel R, Santini V: Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in acute myeloid leukemia. N Engl J Med 328:614, 1993
25. Miyachi H, Takemura Y, Yonekura S, Komatsuda M, Nagao T, Arimori S, Ando Y: MDR1 (multidrug resistance) gene expression in adult acute leukemia: Correlations with blast phenotype. Int J Hematol 57:31, 1993
26. Yang GS, Minden MD, McCulloch EA: Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. Leukemia 8:2065, 1994
27. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Darte M, Daniel MT, Bowen D, Huebner G, Bauters F, Fegueux N, Fey M, Sanz M, Lowenberg B, Maloisel F, Auzanneau G, Sadou A, Gardin C, Bastion T, Ganser A, Kacky E, Dombret H, Chastang C, Degos L, European APL 91 Group: Effect of all transretinoic acid in newly diagnosed acute promyelocytiv leukemia. Results of a multicenter randomized trial. Blood 82:3241, 1993
28. Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, Warrell RP Jr: All-trans retinoic acid for treatment of acute myeloid leukemia: Results of the New York study. Ann Intern Med 120:278, 1994
29. Lotem J, Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 4:41, 1993